Advertisement

Management of Diabetic Dyslipidaemia

  • D. John Betteridge

Keywords: dyslipidaemia, LDL-cholesterol, small dense LDL, HDL-cholesterol, statins, fibrates, ezetimibe, nicotinic acid.

Keywords

Statin Therapy Microsomal Triglyceride Transfer Protein United Kingdom Prospective Diabetes Study Cholesterol Ester Transfer Protein Heart Protection Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zimmet PZ, Alberti KGMM. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet. 1997;350(Suppl. 1):1–4.CrossRefGoogle Scholar
  2. 2.
    Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46:733–749.CrossRefPubMedGoogle Scholar
  3. 3.
    Betteridge DJ. Dyslipidaemia and diabetes Pract Diabetes Int. 2001;18:201–208.Google Scholar
  4. 4.
    Assman E, Schulte H. The prospective cardiovascular Munster (PROCAM) study: prevalence of hyperlipidaemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713–1724.CrossRefGoogle Scholar
  5. 5.
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689.CrossRefPubMedGoogle Scholar
  6. 6.
    Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance in type 2 diabetes. Endcr Rev. 2002;23:201–229.CrossRefGoogle Scholar
  7. 7.
    Despres J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006;8(Suppl. B) B4–B12.CrossRefGoogle Scholar
  8. 8.
    Kadowaki T, Yamamuchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26: 439–451.CrossRefPubMedGoogle Scholar
  9. 9.
    Chirieac DV, Chirieac LR, Corsetti JP, et al. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apo B production. Am J Physiol Endocrinol Metabol. 2000;279: E1003–E1011.Google Scholar
  10. 10.
    Lin MCM, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HEPG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36:1073–1081.PubMedGoogle Scholar
  11. 11.
    Ginsberg HN, Illingworth DG. Postprandial dyslipidaemia; an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol. 2001;88(Suppl 9):9H–15H.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee S-J, Moye LA, Campos H, et al. Hypertri-glyceridaemia but not diabetic status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis. 2003;167:293–302.CrossRefPubMedGoogle Scholar
  13. 13.
    Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–458.CrossRefPubMedGoogle Scholar
  14. 14.
    Ceriello A, Tabga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridaemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation. Effects of short and long-term simvastatin therapy. Circulation. 2002;106:1211–1218.CrossRefPubMedGoogle Scholar
  15. 15.
    Lamarche B, Rashid S, Lewis GF, etal. HDL metabolism in hypertriglyceridaemic states: an overview. Clin Chem Acta.1999;286:145–161.CrossRefGoogle Scholar
  16. 16.
    Toth PP. Adiponectin and high density lipoprotein: a metabolic association through thick and thin. Eur Heart J. 26:1579–1581.Google Scholar
  17. 17.
    Tan KC, Cooper MB, Ling KL, et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis. 1995;113:273–287.CrossRefPubMedGoogle Scholar
  18. 18.
    Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis. 2000;148:151–158.CrossRefPubMedGoogle Scholar
  19. 19.
    Gray RS, Robbins DC, Wang W, et al. Relation of LDL size to insulin resistance syndrome and coronary heart disease in American Indians. Arterioscler Thromb Vasc Biol. 1997;17:2713–2720.PubMedGoogle Scholar
  20. 20.
    Stamler J, Vaccaro O, Neaton JD, et al for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444.CrossRefPubMedGoogle Scholar
  21. 21.
    Turner RC, Millns H, Neil HAW for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ. 1998;316:823–828.PubMedGoogle Scholar
  22. 22.
    Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol is a strong predictor of coronary artery disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000;20:830–835.Google Scholar
  23. 23.
    Chapman MJ, Guerin M, Bruckert E. Atherogenic dense low density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19: (Suppl. A) A24–A30.PubMedGoogle Scholar
  24. 24.
    Chait A, Wight TN. Interaction of native and modified low density lipoproteins with extracellular matrix. Curr Opin Lipidol. 2000;11:451–456.CrossRefGoogle Scholar
  25. 25.
    Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridaemic hyper apoB: the unappreciated atherogenic dyslipidaemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447–459.PubMedGoogle Scholar
  26. 26.
    Steinbrecher UP, Witztum JL. Glycosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984;33:130–134.CrossRefPubMedGoogle Scholar
  27. 27.
    Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.PubMedGoogle Scholar
  28. 28.
    Kreiger M. Scavenger receptor class B type 1 is a multi-ligand HDL receptor that influences diverse physiologic systems. J Clin Invest. 2001;108:793–797.Google Scholar
  29. 29.
    Schmitz G, Kaminski WE. ATP-binding cassette (ABC) transporter in atherosclerosis. Curr Atheroscler Rep. 2002;4:243–251.CrossRefPubMedGoogle Scholar
  30. 30.
    JBS 2 Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl. V):v1–v52.Google Scholar
  31. 31.
    Yusuf S, Hawken S, Ounpuu S, et al. on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet. 2004; 364:937–952.CrossRefPubMedGoogle Scholar
  32. 32.
    Hulley SB, Rosenman RH, Bawal RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383–1389.PubMedCrossRefGoogle Scholar
  33. 33.
    Hokanson E, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level; a meta-analysis of population-based prospective studies. J Cardiovascular Risk. 1996;3:213–219.CrossRefGoogle Scholar
  34. 34.
    Assmann E, Sculte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733–737.CrossRefPubMedGoogle Scholar
  35. 35.
    Manninen V, Tenkanen H, Koskinen P, et al. Joint effects of triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.PubMedGoogle Scholar
  36. 36.
    Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidaemia and hyperglycaemia predict coronary heart disease in middle-aged patients with NIDDM. Diabetes. 1997;46:1354–1359.CrossRefPubMedGoogle Scholar
  37. 37.
    Betteridge DJ, Morrell JM. Lipids and Coronary Heart Disease. Arnold, London. 2003.Google Scholar
  38. 38.
    Betteridge DJ, Khan M. Statins and Coronary Artery Disease. (2nd edition) Science Press. London. 2003.Google Scholar
  39. 39.
    Scandinavian Simvastatin Survival Study Group (4S) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383–1389.Google Scholar
  40. 40.
    Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620.CrossRefPubMedGoogle Scholar
  41. 41.
    Betteridge DJ. Benefits of lipid-lowering therapy in patients with type 2 diabetes Am J Med. 2005;118: (suppl 12A) 10S–15S.CrossRefGoogle Scholar
  42. 42.
    Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-trated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Int Med. 1999;159:2661–2667.CrossRefGoogle Scholar
  43. 43.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–2016.CrossRefGoogle Scholar
  44. 44.
    Athyros VG, Papagrorgious AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program Goal versus “usual”care in secondary coronary heart disease prevention. Curr Med Res Opin. 2002;18:220–228.CrossRefPubMedGoogle Scholar
  45. 45.
    Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495–1504.CrossRefPubMedGoogle Scholar
  46. 46.
    LaRosa JC, Grundy SM, Waters D, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1452–1435.CrossRefGoogle Scholar
  47. 47.
    Shepherd J, Barter P, Carmena R. et al. Effect of lowering LDL cholesterol substantially below recommended levels in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Diabetes Care. 2006;29:1220–1226.CrossRefPubMedGoogle Scholar
  48. 48.
    Deedwania P, Barter P, Carmena R, et al. Reduction of low density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928.CrossRefPubMedGoogle Scholar
  49. 49.
    Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. JACC. 2006;48:438–455.PubMedGoogle Scholar
  50. 50.
    Colhoun HM. Betteridge DJ, Durrington PN, et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–696.CrossRefPubMedGoogle Scholar
  51. 51.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–1158.CrossRefPubMedGoogle Scholar
  52. 52.
    Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA. 1997;278:313–321.CrossRefPubMedGoogle Scholar
  53. 53.
    The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischaemic attack. N Engl J Med. 2006;355:549–559.CrossRefGoogle Scholar
  54. 54.
    Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.PubMedGoogle Scholar
  55. 55.
    Frick MH, Elo O, Haapa K, et al. The Helsinki Heart Study: primary prevention trila with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment changes in risk factors and incidence of coronary heart disease. N. Engl J Med. 1987;317: 1237–1245.PubMedGoogle Scholar
  56. 56.
    Robins SJ, Rubins HB, Collins D, et al. for the Veterans Affairs HDL Intervention Trial (VAHIT). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med. 1999; 241:410–418.CrossRefGoogle Scholar
  57. 57.
    Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27.Google Scholar
  58. 58.
    Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–1160.CrossRefPubMedGoogle Scholar
  59. 59.
    The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial Lancet. 2005;366:1849–1861.Google Scholar
  60. 60.
    Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet. 2005;366:1829–1831.CrossRefPubMedGoogle Scholar
  61. 61.
    Grundy SM, Cleeman JI, Merz CNB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.CrossRefPubMedGoogle Scholar
  62. 62.
    Jones PH, Kafonek S, Laurota I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia (the CURVES study) Am J Cardio.l 1998;81:582–587.CrossRefPubMedGoogle Scholar
  63. 63.
    Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol. 2003;92:152–160.CrossRefPubMedGoogle Scholar
  64. 64.
    Kashani A, Phillips CO, Foody JM, et al. Statin use is associated with a low incidence of adverse events. Circulation. 2006;114:2788–2797.CrossRefPubMedGoogle Scholar
  65. 65.
    Nissen SE, Nicholls Sj, Sipahi I, et al. Effects of very high intensity statin therapy on regression of coronary atherosclerosis. JAMA. 2006;295:1556–1565.CrossRefPubMedGoogle Scholar
  66. 66.
    Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-LikeMayo Clin Proc. (NPC1L1) PNAS. 2005;102:8132–8137.CrossRefPubMedGoogle Scholar
  67. 67.
    Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620–629.CrossRefPubMedGoogle Scholar
  68. 68.
    Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 pateints with primary hypercholesterolaemia. A prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415.CrossRefPubMedGoogle Scholar
  69. 69.
    Hunninghake DB. Bile acid sequestering agents (resins) In: Lipoproteins in Health and Disease. Edotors DJ Betteridge, DR Illingworth, J. Shepherd. Arnold, London. 1999. pp. 1133–1144.Google Scholar
  70. 70.
    Walldius G, Wahlberg G. Nicotinic acid and its derivatives In Lipoproteins in Health and Disease. Editors DJ Betteridge, DR Illingworth, J Shepherd Arnold, London. 1999. pp. 1181–1198.Google Scholar
  71. 71.
    Leiter LA, Betteridge DJ, Chacra AR, et al. on behalf of the AUDIT Study Steering Committee. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes. Br J Diabetes Vasc Dis. 2006;6:31–41.CrossRefGoogle Scholar
  72. 72.
    Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1288.CrossRefPubMedGoogle Scholar
  73. 73.
    Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA. 2006;296:2572–2581. CrossRefPubMedGoogle Scholar
  74. 74.
    Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized, controlled trial. Lancet. 2006 368;368:1660–1672.CrossRefPubMedGoogle Scholar
  75. 75.
    Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med. 2001;345:1583–1592.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • D. John Betteridge
    • 1
  1. 1.Department of MedicineUniversity College London Medical SchoolUK

Personalised recommendations